Intrauterine Contraceptive Devices (IUD) Market Size
Intrauterine Contraceptive Devices (IUD) Market size was at US$ 4.78 billion in 2025 and is expected to reach US$ 6.95 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2026-2033.
An intrauterine device is a small plastic T-shaped device used for birth control. It is inserted into the uterus where it stays to prevent pregnancy. Intrauterine devices prevent sperm from fertilizing an egg and prevent fertilized eggs from implanting in the uterus. The use of intrauterine devices is also being studied in the prevention and treatment of endometrial cancer and other conditions.
Intrauterine devices are one of the most effective forms of contraception available today, with rates of failure similar to various forms of sterilization. There are many benefits of IUDs, including efficacy, ease of use, reversible nature, and patient satisfaction, especially with time commitment for long-term use and cost. This activity reviews the indications, contraindications, risks, and benefits of intrauterine device placement and removal. This activity will also detail the role of the interprofessional team in providing patients who undergo intrauterine device placement and removal with the best possible care.
Executive Summary
For more details on this report - Request for Sample
Intrauterine Contraceptive Devices Market Dynamics: Drivers
Increasing adoption of IUDs is driving the growth of the intrauterine contraceptive devices market
The demand for the intrauterine contraceptive devices (IUDs) market is driven by multiple factors. The increase in awareness among people propels the market growth. Furthermore, the demand for the intrauterine contraceptive devices (IUDs) market will be fueled by technological advancements and government initiatives.
For instance, the United Nations reported that 161 million people worldwide use intrauterine devices (IUDs) as a form of contraception, making it one of the most common methods globally. In the United States, 20.4% of sexually experienced women have ever used an IUD, according to the CDC as of December 2023. In 2016, 14% of contraceptive users between the ages of 15 and 44 in the U.S. used an IUD, up from 2.4% in 2002. Women between the ages of 25 and 29 had the highest rates of IUD use at 19%, while those between 15 and 19 and 45 and 49 had the lowest rates at 5–6%.
Moreover, according to an article posted by the National Institute of Health, in July 2023, the use of the IUD contraceptive method varies widely. 18% in Eastern and southeastern Asia, and Northern Africa, while it is 27.8% in Tunisia and 36.1% in Egypt. Even though the use of modern contraceptive methods has nearly tripled, increasing from 14% to 41% between 2005 and 2019 among married women in Ethiopia, the contribution of an IUD to the method mix is negligible. The utilization of an IUD varies from 5.2% in Addis Ababa to 0.4% in the Gambella region to null in the Somali region of Ethiopia.
Restraints
Factors such as high costs associated with IUDs and side effects caused due to IUDs are expected to hamper the market. Women who use IUDs may experience side effects such as irregular menstrual cycle, increased period bleeding, and worsening of period cramps. In a few cases, it may lead to ectopic pregnancies and pelvic pain.
Intrauterine Contraceptive Devices Market Segmentation Analysis
The global intrauterine contraceptive devices market is segmented based on type, end-user, and region.
The copper IUD segment accounted for approximately 45.8% of the intrauterine contraceptive devices market share
The copper IUD segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.
The non-hormonal copper IUD is a small plastic device with copper wire coiled (wrapped) around the frame. It is inserted into the uterus (womb) where the IUD constantly releases a small amount of copper. The copper IUDs are more than 99% effective at preventing pregnancy and can last for up to 5 – 10 years (depending on the type). A copper IUD can be used for contraception until menopause if inserted when one is 40 years of age or older.
For instance, in October 2023, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD). The data presented at three recent women's health scientific congresses provide further support for the investigational, next-generation, hormone-free IUD as exhibited in its pivotal phase 3 trial. The hormone-free Copper 175 mm2 IUD has a flexible frame made of nitinol, a material that has superelastic properties and allows for the copper to be strategically placed near the Ostia of the fallopian tubes and the internal os of the cervix for proximal effect.
Intrauterine Contraceptive Devices Market Geographical Analysis
North America accounted for approximately 48.6% of the intrauterine contraceptive devices market share
The North America region is expected to hold the largest market share over the forecast period. The growing awareness among people in this region helps to propel the market. Additionally, the United States is known for the presence of major market players, which further accelerates the market growth by developing IUDs by gaining FDA approvals.
For instance, in February 2025, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA (copper intrauterine system) for the prevention of pregnancy in females of reproductive potential for up to three years. MIUDELLA is a next-generation, hormone-free, low-dose copper intrauterine device or IUD, the first to be approved by the FDA in the United States in over 40 years.
Market Segmentation
By Type
Hormonal IUD
Copper IUD
By End-User
Hospitals
Gynecology Clinics
Community Healthcare Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Intrauterine Contraceptive Devices Market Major Players
The major global players in the global intrauterine contraceptive devices (IUD) market include Teva Pharmaceuticals, Bayer, Pregna, Sebela Pharmaceuticals, CooperSurgical, Inc., AbbVie, Eurogine, and SMB Corporation, among others.
Key Developments in the Intrauterine Contraceptive Devices (IUD) Market
September 2026: Organon advanced MIUDELLA® development by securing FDA review of an application to extend its approved duration from 3 to 6 years. The hormone-free copper IUD uses Sebela Women’s Health’s flexible-frame and preloaded-inserter technology, with a regulatory decision expected in Q2 2027.
- August 2026: Organon opened the MIUDELLA® REMS program ahead of its anticipated U.S. commercial launch. The initiative enables healthcare providers, healthcare settings and eligible specialty pharmacies to complete required training and certification for the new hormone-free copper IUD.
- June 2026: Organon completed its global licensing agreement for MIUDELLA® from Sebela Pharmaceuticals. The deal gives Organon exclusive global rights to the hormone-free copper IUD, which incorporates a flexible frame and fully preloaded inserter with a 3.7-mm tapered insertion tube.
- February 2026: Organon announced an agreement to exclusively license global rights to MIUDELLA®, expanding its long-acting contraceptive portfolio. MIUDELLA was highlighted for its hormone-free copper design, flexible frame and preloaded inserter intended to provide an alternative IUD option.
Key Takeaways
- The growing preference for highly effective, long-acting and reversible contraception is emerging as a key market trend, supported by the convenience, extended duration of protection, reversibility, and reduced reliance on daily user adherence associated with intrauterine contraceptive devices.
- North America maintains a leading position, accounting for approximately 48.6% of the global market share, supported by greater awareness of intrauterine contraception, established healthcare infrastructure, broad access to reproductive healthcare services, and continued regulatory activity surrounding new IUD technologies.
- Asia-Pacific is projected to experience the fastest growth, driven by increasing awareness of modern contraceptive methods, expanding healthcare access, government-supported family-planning initiatives, and improving availability of intrauterine contraceptive services across developing healthcare systems.
- Copper and hormonal IUDs continue to address distinct contraceptive preferences, with copper devices providing a hormone-free option while hormonal systems offer long-term contraception and can provide additional benefits such as reduced menstrual bleeding and cramping for some users.
- Increasing investments in device innovation are encouraging the development of IUD designs and insertion technologies focused on improving placement, patient comfort, usability, duration of protection, and overall clinical experience.
- Expansion of contraceptive access through hospitals, gynecology clinics, and community healthcare centers is creating additional opportunities, particularly where public-health programs and reproductive-health services are strengthening access to long-acting reversible contraception.
- The market is also benefiting from increasing emphasis on informed contraceptive choice, provider education, improved patient counseling, and broader reproductive-health initiatives, while factors such as insertion-related discomfort, potential side effects, cost considerations, and uneven access to trained providers remain important considerations for wider adoption.
Intrauterine Contraceptive Devices (IUD) Market Scope
Metrics | Details |
CAGR | 4.8% |
Market Size | 2023-2033 |
Market Estimation Forecast Period | 2026-2033 |
Revenue Units | Value (US$ Bn) |
Segments Covered | Type and End-User |
Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa |
Largest Region | North America |
Fastest Growing Region | Asia-Pacific |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
The global intrauterine contraceptive devices market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Why Choose DataM?
- Technological Innovations: Explores advancements in intrauterine contraceptive device technologies, including copper-bearing IUDs and levonorgestrel-releasing intrauterine systems (IUS), with a focus on device design, hormone-release mechanisms, materials, insertion systems, size and configuration, and innovations aimed at improving contraceptive effectiveness, duration of use, user experience, and clinical usability. WHO identifies copper-bearing and levonorgestrel-releasing devices as the two principal IUD categories.
- Product Performance & Market Positioning: Evaluates IUD products based on critical parameters such as contraceptive effectiveness, duration of protection, hormone or copper delivery, device dimensions, insertion characteristics, safety profile, reversibility, and suitability across different patient populations, highlighting how manufacturers differentiate products through device design, duration of use, hormonal dosage, and clinical applications. Current regulatory evidence demonstrates differentiation among levonorgestrel-releasing systems and copper IUDs in terms of formulation, dimensions, and approved duration.
- Real-World Evidence: Highlights the adoption of IUDs across family-planning services, reproductive-health clinics, hospitals, gynecology practices, and other healthcare settings, examining their use as long-acting reversible contraception and, for copper-bearing devices, as emergency contraception. WHO reports that both copper and hormonal IUDs are highly effective, with fewer than one pregnancy per 100 women in the first year of use.
- Market Updates & Industry Changes: Tracks key developments such as new IUD product introductions, regulatory approvals and label expansions, clinical evidence, contraceptive-access initiatives, manufacturing and supply developments, healthcare-program adoption, and changes in international recommendations. WHO's 2025 updated practice recommendations include specific guidance concerning IUD use, while its September 2026 expansion of medical-device prequalification includes contraceptives, reflecting continued emphasis on quality-assured access to contraceptive products.
- Competitive Strategies: Analyzes how leading IUD manufacturers and contraceptive healthcare companies strengthen their market presence through product innovation, clinical research, regulatory approvals, portfolio expansion, strategic partnerships, manufacturing capabilities, healthcare-provider engagement, and initiatives designed to improve access to long-acting reversible contraception across developed and emerging markets.
- Pricing & Market Access: Explains pricing variations across IUD products according to device type, copper or hormonal formulation, duration of contraceptive protection, product design, regulatory requirements, procurement volumes, healthcare setting, and geographic market, while examining market access through hospitals, gynecology and family-planning clinics, public-health programs, distributors, pharmacies where applicable, and institutional procurement channels. WHO emphasizes quality, safety, and performance assessment as important considerations for global procurement and access to contraceptive medical devices.
- Market Entry & Expansion: Identifies growth opportunities driven by demand for long-acting reversible contraception, increasing access to family-planning services, preference for effective and reversible contraceptive options, expansion of reproductive-health infrastructure, and continued inclusion of IUDs within national and international family-planning programs. It also assesses expansion strategies such as regulatory approvals, local distribution partnerships, public-sector procurement, healthcare-provider training, manufacturing localization, and development of differentiated copper and levonorgestrel-releasing products.
Target Audience
- Intrauterine Contraceptive Device Manufacturers
- Pharmaceutical & Women's Health Companies
- Medical Device Manufacturers & Developers
- Gynecology & Reproductive Healthcare Providers
- Hospitals & Family Planning Clinics
- Public Health & Family Planning Organizations
